Result of GM

RNS Number : 7632P
Immupharma PLC
22 February 2016
 

                                                                                                                                                              22 FEBRUARY 2016

ImmuPharma PLC

 

Result of GM

 

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed.

Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to have received such support from our existing shareholders and new investors in this placing to fund our pivotal Phase III Lupuzor™ trial. Having recently announced that we have commenced dosing our first Lupus patients in the US, we look forward to providing regular updates on the trial through this year and 2017."

 

For further information please see the Company's website, www.immupharma.org, or contact:

ImmuPharma plc

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

 

 

+ 44 (0) 20 7152 4080

 

+ 44 (0) 7721 413496

lisa.baderoon@immupharma.com

Panmure Gordon (Financial Adviser, Nominated Adviser & Broker)

Fred Walsh, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

+44 (0) 20 7886 2500

 

All defined terms used in this announcement are defined, unless otherwise defined here, in the appendix to the Proposed Placing and Subscription and Notice of General Meeting announcement made on 5 February 2016.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REGBXGDDIXDBGLD

Companies

Immupharma (IMM)
UK 100

Latest directors dealings